00:00:58 EDT Thu 13 Jun 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Resverlogix Corp
Symbol RVX
Shares Issued 269,501,296
Close 2023-06-20 C$ 0.10
Market Cap C$ 26,950,130
Recent Sedar Documents

Resverlogix shareholders elect five directors at AGM

2023-06-20 18:18 ET - News Release

Mr. Donald McCaffrey reports

RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2023 MEETING OF SHAREHOLDERS

Resverlogix Corp. has held its annual meeting of shareholders in Calgary, Alta.

During business proceedings at the meeting, shareholders elected five board members until the next annual meeting. The voting results of shares represented at the meeting for individual directors are set out in the attached table.

                         Votes for   Votes withheld   Per cent for   Per cent withheld

Donald J. McCaffrey    122,884,287       11,547,550          91.41%               8.59%      
Shawn Lu               123,340,266       11,091,571          91.75%               8.25%      
Kelly McNeill          127,204,762        7,227,075          94.62%               5.38%      
Siu Lun (Dicky) To     127,856,904        6,574,933          95.11%               4.89%      
Kenneth Zuerblis       129,096,743        5,335,094          96.03%               3.97%      

Resverlogix shareholders approved all resolutions outlined in the notice of meeting and management information circular dated May 10, 2023. The information circular is available on SEDAR and on the Resverlogix website.

A webcast archive of the executive presentation portion of the meeting will be available.

About Resverlogix Corp.

Founded in 2001, Resverlogix is a Calgary-based, late-stage, biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Its new class of epigenetic therapies are designed to regulate the expression of disease-causing genes. It aims to improve patients' lives by restoring biological functions -- altered by serious illnesses such as cardiovascular disease -- back to a healthier state.

The company's clinical program is focused on evaluating its lead candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions.

Resverlogix common shares trade on the Toronto Stock Exchange (RVX).

© 2024 Canjex Publishing Ltd. All rights reserved.